A detailed history of Geode Capital Management, LLC transactions in Autolus Therapeutics PLC stock. As of the latest transaction made, Geode Capital Management, LLC holds 86,256 shares of AUTL stock, worth $197,526. This represents 0.0% of its overall portfolio holdings.

Number of Shares
86,256
Previous 86,256 -0.0%
Holding current value
$197,526
Previous $300,000 4.33%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 13, 2023

SELL
$2.32 - $3.36 $61,918 - $89,675
-26,689 Reduced 23.63%
86,256 $200,000
Q2 2023

Aug 11, 2023

BUY
$1.64 - $3.21 $97,102 - $190,060
59,209 Added 110.18%
112,945 $268,000
Q4 2022

Feb 13, 2023

SELL
$1.74 - $3.27 $138,681 - $260,625
-79,702 Reduced 59.73%
53,736 $102,000
Q1 2022

May 13, 2022

SELL
$3.52 - $5.46 $228,965 - $355,156
-65,047 Reduced 32.77%
133,438 $556,000
Q4 2021

Feb 11, 2022

BUY
$5.1 - $7.0 $693,375 - $951,692
135,956 Added 217.43%
198,485 $1.03 Million
Q3 2021

Nov 12, 2021

BUY
$5.32 - $7.37 $76,432 - $105,884
14,367 Added 29.83%
62,529 $409,000
Q2 2021

Aug 13, 2021

BUY
$4.78 - $7.96 $154,771 - $257,736
32,379 Added 205.15%
48,162 $319,000
Q4 2020

Feb 12, 2021

SELL
$8.13 - $12.79 $33,820 - $53,206
-4,160 Reduced 20.86%
15,783 $141,000
Q1 2020

May 14, 2020

BUY
$4.2 - $13.0 $3,351 - $10,374
798 Added 4.17%
19,943 $119,000
Q4 2019

Feb 13, 2020

BUY
$11.13 - $16.28 $86,958 - $127,195
7,813 Added 68.95%
19,145 $252,000
Q2 2019

Aug 14, 2019

BUY
$15.1 - $31.25 $22,967 - $47,531
1,521 Added 15.5%
11,332 $182,000
Q4 2018

Feb 13, 2019

BUY
$24.21 - $48.01 $237,524 - $471,026
9,811 New
9,811 $322,000

Others Institutions Holding AUTL

About Autolus Therapeutics plc


  • Ticker AUTL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 90,909,800
  • Market Cap $208M
  • Description
  • Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which...
More about AUTL
Track This Portfolio

Track Geode Capital Management, LLC Portfolio

Follow Geode Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.